Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Amarantus Bioscience Holdings, Inc. (AMBS) Starts Presentation at SeeThruEquity Conference

Amarantus BioScience Holdings (OTC: AMBS) is a biotech company focused on developing therapeutic products with potential for orphan drug designation in neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company’s lead therapeutic program is indicated for the treatment of problems associated with Parkinson’s. It also haves exclusive worldwide license rights of Engineered Skin Substitute for severe burns. Amarantus’ lead neurological diagnostic product is indicated to diagnose Alzheimer’s disease. The company is actively exploring strategic options for Amarantus Diagnostics, including a potential spin-off, to derive the full value of its neuro-diagnostics business. For more information, visit the company’s website at

The 5th Annual SeeThruEquity conference, held in New York City, will connect more than 50 presenting companies with microcap-focused investors, sponsors, and industry professionals in attendance. The conference will feature 30-minute presentations by presenting companies, as well as one-on-one meetings with investors. In addition to the large number of companies confirmed to present, SeeThruEquity is hosting a panel composed of industry leaders. For more information on SeeThruEquity, visit
This entry was posted in SeeThruEquity Conference. Bookmark the permalink.

Comments are closed.